<div id="readability-page-1"><p>Shares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) have been assigned an average recommendation of &#34;Moderate Buy&#34; from the fifteen analysts that are presently  covering the firm, Marketbeat.com reports. One analyst  has rated the stock with a sell recommendation, two have given a hold recommendation, eleven have issued  a buy recommendation and one  has issued  a strong buy recommendation on  the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $60.5833.</p><ul><li>Discover the 3 Best-Performing Biotech IPO Stocks of 2024</li></ul><p>A number of analysts have commented on CGON shares. JPMorgan Chase &amp; Co. upped their price objective on shares of CG Oncology from $41.00 to $47.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, September 26th. Wall Street Zen raised shares of CG Oncology from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Friday, October 3rd. HC Wainwright  restated a &#34;buy&#34; rating and issued a $75.00 price objective on shares of CG Oncology in a report on Monday, September 15th. Wedbush started coverage on shares of CG Oncology in a research report on Thursday. They issued an &#34;outperform&#34; rating and a $70.00 target price for the company. Finally, Royal Bank Of Canada raised their price target on shares of CG Oncology from $53.00 to $61.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, November 17th.</p><p><b>View Our Latest Analysis on CG Oncology</b></p><h2>Insider Buying and Selling</h2><p>In related news, Director James Mulay sold 19,112 shares of the stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $39.01, for a total transaction of $745,559.12. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, Director Leonard E. Post sold 5,000 shares of the firm's stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $40.09, for a total transaction of $200,450.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 47,344 shares of company stock worth $1,886,331 over the last three months. </p><h2>Institutional Investors Weigh In On CG Oncology</h2><p>Several institutional investors and hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its position in  CG Oncology by 2.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 439,278 shares of the company's stock worth $10,758,000 after purchasing an additional 11,518 shares in the last quarter.  Swiss National Bank grew its stake in shares of  CG Oncology by 1.9% in the 1st quarter. Swiss National Bank now owns 81,100 shares of the company's stock valued at $1,986,000 after purchasing an additional 1,500 shares during the period.  Invesco Ltd. raised its holdings in shares of  CG Oncology by 2.5% in the 1st quarter. Invesco Ltd. now owns 27,754 shares of the company's stock worth $680,000 after buying an additional 685 shares in the last quarter.  Nuveen LLC bought a new position in shares of  CG Oncology during the 1st quarter worth approximately $4,084,000.  Finally, Fox Run Management L.L.C. acquired a new stake in  CG Oncology in the 1st quarter valued at $408,000. Institutional investors own  26.56% of the company's stock. </p><h2>CG Oncology Trading Down 1.6%</h2><p>Shares of CG Oncology stock opened at $40.94 on Monday. CG Oncology has a 52 week low of $14.80 and a 52 week high of $46.01. The stock has a market cap of $3.30 billion, a PE ratio of -20.07 and a beta of 1.29. The company's 50-day moving average price is $42.01 and its two-hundred day moving average price is $33.36. </p><p>CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.57). The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.07 million. CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 21.67%.  On average, equities analysts predict that  CG Oncology will post -1.31 EPS for the current fiscal year. </p><h2>About CG Oncology</h2> (Get Free Report)<p>CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than CG Oncology</li><li>Which Wall Street Analysts are the Most Accurate?</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>How Can Investors Benefit From After-Hours Trading</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>What is a Dividend Harvesting Strategy and How Can Investors Profit from it?</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dPTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CG Oncology Right Now?</h2><p>Before you consider CG Oncology, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.</p><p>While CG Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CGON

<p>Shares of CG Oncology, Inc. (NASDAQ:CGON) have been given an average recommendation of "Moderate Buy" by fifteen analysts. The average twelve-month price target is $60.58. Recent analyst ratings include JPMorgan's "overweight" with a $47 target, HC Wainwright's "buy" with a $75 target, and Royal Bank of Canada's "outperform" with a $61 target. Insider transactions include sales by Directors James Mulay and Leonard E. Post. Institutional investors own 26.56% of the stock. CG Oncology reported Q3 earnings of ($0.57) per share and revenue of $0.16 million.</p>

CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Moderate Buy" by Brokerages